SAN CARLOS, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast a business overview and update by Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Iovance Biotherapeutics at the following upcoming investor conferences:
  • Rodman & Renshaw 19 th Annual Global Investment Conference in New York, NY on Monday, September 11, 2017 at 11:40 a.m. ET
  • 2017 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Monday, September 25, 2017 at 8:00 a.m. ET

A live audio webcast of both presentations will be available by visiting the Investors section Iovance Biotherapeutics' website at  http://ir.iovance.com/. A replay of the webcast will be archived on Iovance Biotherapeutics' website for 30 days following the presentation.

About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit  http://www.iovance.com.
Investor Relations Contact: Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah@sternir.comMedia Relations Contact:Evan Smith/Kotaro YoshidaFTI Consulting212-850-5622/212-850-5690 evan.smith@fticonsulting.comkotaro.yoshida@fticonsulting.com 

Primary Logo